» Articles » PMID: 32377085

Surgical Treatment of Primary Hyperparathyroidism: Which Therapy to Whom?

Overview
Specialty General Medicine
Date 2020 May 8
PMID 32377085
Citations 11
Authors
Affiliations
Soon will be listed here.
Abstract

Primary hyperparathyroidism (pHPT) is characterized by an increase in the levels of PTH and Ca, or one of these (Ca, PTH) as a result of a dysregulation of calcium (Ca) metabolism due to inappropriate excess parathyroid hormone (PTH) autonomously produced from one or more than one parathyroid glands. Ninety to 95% of pHPT is a sporadic type, which is not associated with the familial history and other endocrine organ tumors, and 5-10% of it is hereditary. While 80-85% of pHPT arises from a single parathyroid adenoma, 4-5% is caused by a double adenoma, 10-15% by multigland hyperplasia and less than 1% by parathyroid cancer. The diagnosis of pHPT is reached biochemically. The only curative treatment of pHPT is surgery. The choice of surgery in pHPT may vary depending on whether the patient has hereditary HPT or thyroid disease requiring surgical treatment, preoperative localization studies and the findings in these studies, the possibilities of using intraoperative PTH and the preference of the surgeon. The preoperatively determined surgical strategy can be revised according to intraoperative findings in case of need to achieve excellent results. The two main approaches in the surgical treatment of pHPT are BNE (bilateral neck exploration) and MIP (minimal invasive parathyroidectomy). Although BNE is a consistently valid option that has excellent results in the surgical treatment of pHPT and is considered the gold standard, MIP is the ideal approach in selected patients with clinically and radiologically considered a single-gland disease. Negative imaging is not a contraindication for parathyroid surgery and is not a criterion for the presence or absence of surgical indication. Although both methods are safe and effective in the surgical treatment of sporadic pHPT, there is still controversy regarding the effectiveness of both methods. Surgical intervention should establish the risk-benefit balance well, minimize the risk of persistent and recurrent disease and provide the highest cure rate without increasing the risk of complications. Complication rates are higher in the secondary surgery, thus in secondary procedures, selective surgery should be performed under guidance of an imaging modality. The surgical strategy should be determined to achieve maximum cure with minimum dissection and minimal morbidity. In this study, we aimed to determine the type of surgical treatment and pHPT patients suitable for the surgical treatment.

Citing Articles

Postoperative pancytopenia in a patient with giant parathyroid adenoma and brown tumor: a case report.

Pan W, Zhao Z, Wang K, He Z, Ou L BMC Endocr Disord. 2024; 24(1):208.

PMID: 39350103 PMC: 11443691. DOI: 10.1186/s12902-024-01742-x.


Hypercalcemic Crisis Due to a Giant Intrathyroidal Parathyroid Adenoma, with Postsurgical Severe Hypocalcemia and Hungry Bone Syndrome: A Case Report.

Papanikos V, Papadodima E, Bantouna D, Paparodis R, Livadas S, Angelopoulos N Clin Pract. 2024; 14(1):179-187.

PMID: 38391401 PMC: 10888302. DOI: 10.3390/clinpract14010015.


Accuracy of Four-Dimensional Computed Tomography and Different Imaging Modalities in Primary Hyperparathyroidism.

Merdad M, Mogharbel A, AlQurashi Y, Nujoom M, Wazzan M, Abduljabbar A Cureus. 2024; 15(12):e50423.

PMID: 38222216 PMC: 10784756. DOI: 10.7759/cureus.50423.


A New Technique for Localization of Parathyroid Adenoma: Infrared Thermal Scanning of the Neck.

Senturk A, Aysan E Cureus. 2023; 15(10):e47977.

PMID: 38034183 PMC: 10686241. DOI: 10.7759/cureus.47977.


Multiple endocrine neoplasia type 4 (MEN4): a thorough update on the latest and least known men syndrome.

Ruggeri R, Benevento E, De Cicco F, Grossrubatscher E, Hasballa I, Tarsitano M Endocrine. 2023; 82(3):480-490.

PMID: 37632635 DOI: 10.1007/s12020-023-03497-2.


References
1.
Bobanga I, McHenry C . Is intraoperative parathyroid hormone monitoring necessary for primary hyperparathyroidism with concordant preoperative imaging?. Am J Surg. 2016; 213(3):484-488. DOI: 10.1016/j.amjsurg.2016.11.035. View

2.
Eastell R, Brandi M, Costa A, DAmour P, Shoback D, Thakker R . Diagnosis of asymptomatic primary hyperparathyroidism: proceedings of the Fourth International Workshop. J Clin Endocrinol Metab. 2014; 99(10):3570-9. DOI: 10.1210/jc.2014-1414. View

3.
Dennison A, Ball M, Dudley N . Preoperative percutaneous localisation of parathyroid tumours: a preliminary report. Ann R Coll Surg Engl. 1985; 67(5):276-8. PMC: 2499541. View

4.
COPE O . The story of hyperparathyroidism at the Massachusetts General Hospital. N Engl J Med. 1966; 274(21):1174-82. DOI: 10.1056/NEJM196605262742105. View

5.
Nussbaum S, Thompson A, Hutcheson K, Gaz R, Wang C . Intraoperative measurement of parathyroid hormone in the surgical management of hyperparathyroidism. Surgery. 1988; 104(6):1121-7. View